Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

663.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28
Open 663.09
Bid (Size) 655.00 (40)
Ask (Size) 674.57 (40)
Prev. Close 663.09
Today's Range 663.09 - 663.09
52wk Range 541.00 - 821.11
Shares Outstanding 91,779,465
Dividend Yield 0.57%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Large-Cap Stock with Exciting Potential and 2 We Turn Down
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m... 
Via StockStory
News headline image
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
Analysts have given Alnylam Pharmaceuticals an average price target of $436. 
Via The Motley Fool

Performance

YTD
-14.6%
-14.6%
1 Month
+7.8%
+7.8%
3 Month
-11.2%
-11.2%
6 Month
-13.7%
-13.7%
1 Year
+16.2%
+16.2%

More News

Read More
News headline image
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% ↗
Via The Motley Fool
REGN (NASDAQ:REGN) Presents a Classic Value Opportunity with Strong Fundamentals ↗
Via Chartmill
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗
Via Chartmill
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
Via The Motley Fool
News headline image
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Underrated Weight Loss Stocks to Buy and Hold ↗
Via The Motley Fool
News headline image
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This Stock Is Up 58% This Year. Is It too Late to Buy? ↗
Via The Motley Fool
News headline image
3 Profitable Stocks We Think Twice About
Via StockStory
News headline image
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
From Pomerantz LLP
Via GlobeNewswire
Top S&P500 movers in Monday's session ↗
Via Chartmill
News headline image
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Regeneron (REGN) Stock Is Trading Up Today
Via StockStory
News headline image
2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky
Via StockStory
Topics Stocks
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
3 Nasdaq 100 Stocks We Find Risky
Via StockStory
News headline image
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN): Grabar Law Office is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Important Notice to Long-Term Shareholders of Molina Healthcare, Inc. (NYSE: MOH); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Grabar Law Office is Investigating Claims on
From Grabar Law Office
Via GlobeNewswire

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 663.09
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 07/13/26 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 60.86B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 61B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.